CARE1 is growing in the UK! New participating site now open: • Royal Free London Expanding access to our EU-funded phase III pragmatic trial addressing a key question in 1L mRCC: IO-IO or IO-TKI? #clinicalresearch #oncology #RCC #clinicaltrials #care1pct #care1project @ikccorg.bsky.social

CARE1 is growing in the Netherlands 🇳🇱 New participating sites now open: • Maastricht UMC+ • Leiden University Medical Center Expanding access to our EU-funded phase III pragmatic trial tackling a key question in 1L mRCC: IO-IO or IO-TKI? #clinicaltrials #oncology #RCC #care1project #care1pct

Dr. Nguyen from City of Hope highlighting during #ASCO26 pRCC educational session the *role of PD-L1 IHC *staining as a candidate *biomarker* to enrich for response to IO… This is the running hypothesis being prospectively tested in CARE-1 PCT in ccRCC in first line setting.

CARE1 PI's at ASCO 2026 🔬 IO-IO or IO-TKI in 1L mRCC? We still lack biomarkers to guide treatment choice. 👉 CARE1, an EU-funded phase III pragmatic trial, is the only head-to-head randomized study addressing this key question. #ASCO2026 #clinicaltrials #oncology #care1project #care1pct

On #ClinicalTrialsDay, we recognize the vital role of clinical research in transforming cancer care. CARE1 – Pragmatic Clinical Trial contributes to advancing research and supporting improved patient outcomes. #WorldCancerResearchDay #CancerResearch #ClinicalTrials #CARE1 #CTD2026

We were proud to hear CARE1 referenced during the session “Navigating the Maze: Clinical Trials and Second‑Line Therapy Decisions" at #IKCSEU26! Many thanks to Bernard Escudier, member of our Patient Advisory Board, for bringing his experience and perspective! #CARE1 #Project ClinicalResearch

At #IKCSEU26, Olivier Exertier highlighted the amazing contribution of patient representatives like @ikccorg.bsky.social and Asso ARTuR in designing EU‑funded programmes such as #CARE1Project. @oncoalert.bsky.social #KidneyCancerAssociation @actionkidneycancer.bsky.social

Insightful discussion at #IKCSEU Paris. During the session on Molecular Biomarkers and Patient Stratification, Yann Vano shared how the CARE1 trial could help clarify whether PD‑L1 can be used as a decision tool in routine therapeutics. #CARE1 @oncoalert.bsky.social #KidneyCancerAssociation

Prof. Laurence Albiges presenting the CARE1 Pragmatic Clinical Trial at the @aacrjournals.bsky.social Special Conference on RAS Oncogenesis & Therapeutics. #AACR #CARE1 #RCC #ClinicalTrials #CancerResearch @turajliclab.bsky.social

Discover the CARE1 Project as described by Pr. Laurence Albiges 👇 youtu.be/9FdMV6CJ4uM?... via @YouTube

You can also follow us on our other platforms: • LinkedIn: www.linkedin.com/company/care... • Facebook: www.facebook.com/profile.php?... • X: x.com: x.com/CARE1project • Website: care1project.com • Youtube: www.youtube.com/@CARE1_EU Looking forward to sharing our journey with the Bluesky community!

👋 Hello Bluesky! We’re excited to launch the official account for the CARE1 Project, a joint collaboration from moe than 10 European institutions working together to optimize treatment for patients with metastatic renal cell carcinoma. CARE1 is currently active across Europe!